ProCE Banner Activity

An Expert Tour of Recent Developments in Early-Stage Breast Cancer

Clinical Thought
Management of early-stage breast cancer is rapidly evolving with perioperative options now including abemaciclib, olaparib, and pembrolizumab. In this commentary, Heather McArthur, MD, MPH, shares key takeaways on the latest developments.

Released: August 04, 2022

Expiration: August 03, 2023

Share

Faculty

Heather McArthur

Heather McArthur, MD, MPH

Associate Professor
Department of Medicine
Komen Distinguished Chair in Clinical Breast Cancer
Clinical Director Breast Cancer Program
Harold C. Simmons Comprehensive Cancer Center
UT Southwestern Medical Center
Dallas, Texas

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Lilly

Merck Sharp & Dohme Corp

Program Director Disclosure

Program Director

Heather McArthur, MD, MPH

Associate Professor
Department of Medicine
Komen Distinguished Chair in Clinical Breast Cancer
Clinical Director Breast Cancer Program
Harold C. Simmons Comprehensive Cancer Center
UT Southwestern Medical Center
Dallas, Texas

Heather McArthur, MD, MPH: consultant/advisor/speaker: AstraZeneca, Bristol-Myers Squibb, Crown Bioscience, Daiichi Sankyo, Gilead Sciences, Immunomedics, Lilly, Merck, Pfizer, Puma Biotech, Seattle Genetics; researcher: Bristol-Myers Squibb, Merck.